Table of Contents Table of Contents
Previous Page  488 / 604 Next Page
Information
Show Menu
Previous Page 488 / 604 Next Page
Page Background

Phase II or retrospec+ve cohorts

Author; year

Design

Pts

Dose/frx

m-­‐FU

Locol control

(%)

Survival 1,2

years

1, 2 years (%)

Wulf 2004

Dose esc.

41

3x10-­‐12.5 Gy

1x26 Gy

9 mts

80

85, 33

Hof 2007

Phase I/II

61

1x12-­‐30 Gy

14 mts

83

(>26 Gy and

<10cc)

78, 65

Rusthoven 2009 Phase I/II

38

3x16-­‐20 Gy

15 mts

96

65, 39

Zhang 2011

Retrospect

71

3-­‐5x12 Gy

25 mts

97, 89

79, 41 (3 yr)

Ricardi 2012

Retrospect

61

1x26 Gy,

3x15 Gy,

4x9 Gy

20 mts

89

79, 67

Comito 2014

Phase II

40

4x12 –

3x25 Gy

24

80

80, 65

DeVin 2014

Retrospect

56

10x4-­‐5 Gy

12 mts

33

(incl brain)

55 (2 yr)

Takahachi 2014 Carbon ions

Feasibility

34

12x5 Gy

1x44 Gy

24 mts

85

90, 65

Fode 2015

Retrospect

92

3x15-­‐22.5 Gy

29

LR: 13

80, 58

Guckenberger/

DEGRO (abstract)

Retrospect

Mul+-­‐inst

715

NA

NA

NA

53 (2 yr)

24 (5 yr)

Lung mets: Local control rates 80-­‐96%